vs
EXACT SCIENCES CORP（EXAS）与Vestis Corp（VSTS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Vestis Corp的1.3倍（$878.4M vs $663.4M），Vestis Corp净利率更高（-1.0% vs -9.8%，领先8.8%），EXACT SCIENCES CORP同比增速更快（23.1% vs -3.0%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $28.3M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -3.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Vestis Corp是北美领先的工作制服、安全防护服饰及配套设施服务供应商，服务覆盖医疗、制造、零售、餐饮住宿、公共服务等多个领域，为企业客户提供定制化的制服租赁、清洁与日常维护解决方案。
EXAS vs VSTS — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$663.4M
营收增速更快
EXAS
高出26.1%
-3.0%
净利率更高
VSTS
高出8.8%
-9.8%
自由现金流更多
EXAS
多$92.1M
$28.3M
两年增速更快
EXAS
近两年复合增速
-3.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $663.4M |
| 净利润 | $-86.0M | $-6.4M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 2.5% |
| 净利率 | -9.8% | -1.0% |
| 营收同比 | 23.1% | -3.0% |
| 净利润同比 | 90.1% | -868.1% |
| 每股收益（稀释后） | $-0.45 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASVSTS
| Q1 26 | — | $663.4M | ||
| Q4 25 | $878.4M | $712.0M | ||
| Q3 25 | $850.7M | — | ||
| Q2 25 | $811.1M | $673.8M | ||
| Q1 25 | $706.8M | $665.2M | ||
| Q4 24 | $713.4M | $683.8M | ||
| Q3 24 | $708.7M | $684.3M | ||
| Q2 24 | $699.3M | $698.2M |
净利润EXASVSTS
| Q1 26 | — | $-6.4M | ||
| Q4 25 | $-86.0M | $-12.5M | ||
| Q3 25 | $-19.6M | — | ||
| Q2 25 | $-1.2M | $-676.0K | ||
| Q1 25 | $-101.2M | $-27.8M | ||
| Q4 24 | $-864.6M | $832.0K | ||
| Q3 24 | $-38.2M | $-2.3M | ||
| Q2 24 | $-15.8M | $5.0M |
毛利率EXASVSTS
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASVSTS
| Q1 26 | — | 2.5% | ||
| Q4 25 | -9.4% | 2.5% | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | -0.3% | 3.7% | ||
| Q1 25 | -13.6% | -1.3% | ||
| Q4 24 | -122.8% | 4.4% | ||
| Q3 24 | -5.6% | 4.4% | ||
| Q2 24 | -3.8% | 5.4% |
净利率EXASVSTS
| Q1 26 | — | -1.0% | ||
| Q4 25 | -9.8% | -1.8% | ||
| Q3 25 | -2.3% | — | ||
| Q2 25 | -0.1% | -0.1% | ||
| Q1 25 | -14.3% | -4.2% | ||
| Q4 24 | -121.2% | 0.1% | ||
| Q3 24 | -5.4% | -0.3% | ||
| Q2 24 | -2.3% | 0.7% |
每股收益（稀释后）EXASVSTS
| Q1 26 | — | $-0.05 | ||
| Q4 25 | $-0.45 | $-0.10 | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | $-0.01 | ||
| Q1 25 | $-0.54 | $-0.21 | ||
| Q4 24 | $-4.69 | $0.01 | ||
| Q3 24 | $-0.21 | $-0.02 | ||
| Q2 24 | $-0.09 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $41.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $864.4M |
| 总资产 | $5.9B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASVSTS
| Q1 26 | — | $41.5M | ||
| Q4 25 | $964.7M | $29.7M | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | $23.7M | ||
| Q1 25 | $786.2M | $28.8M | ||
| Q4 24 | $1.0B | $18.6M | ||
| Q3 24 | $1.0B | $31.0M | ||
| Q2 24 | $946.8M | $29.1M |
总债务EXASVSTS
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | — |
股东权益EXASVSTS
| Q1 26 | — | $864.4M | ||
| Q4 25 | $2.4B | $865.6M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | $882.2M | ||
| Q1 25 | $2.4B | $876.3M | ||
| Q4 24 | $2.4B | $899.6M | ||
| Q3 24 | $3.2B | $903.1M | ||
| Q2 24 | $3.2B | $901.2M |
总资产EXASVSTS
| Q1 26 | — | $2.9B | ||
| Q4 25 | $5.9B | $2.9B | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $5.8B | $2.9B | ||
| Q1 25 | $5.7B | $2.9B | ||
| Q4 24 | $5.9B | $2.9B | ||
| Q3 24 | $6.7B | $2.9B | ||
| Q2 24 | $6.7B | $3.1B |
负债/权益比EXASVSTS
| Q1 26 | — | — | ||
| Q4 25 | — | 1.35× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $37.7M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $28.3M |
| 自由现金流率自由现金流/营收 | 13.7% | 4.3% |
| 资本支出强度资本支出/营收 | 3.6% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $45.0M |
8季度趋势，按日历期对齐
经营现金流EXASVSTS
| Q1 26 | — | $37.7M | ||
| Q4 25 | $151.7M | $30.9M | ||
| Q3 25 | $219.9M | — | ||
| Q2 25 | $89.0M | $22.9M | ||
| Q1 25 | $30.8M | $6.7M | ||
| Q4 24 | $47.1M | $3.8M | ||
| Q3 24 | $138.7M | $295.6M | ||
| Q2 24 | $107.1M | $48.7M |
自由现金流EXASVSTS
| Q1 26 | — | $28.3M | ||
| Q4 25 | $120.4M | $15.6M | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | $8.0M | ||
| Q1 25 | $-365.0K | $-6.9M | ||
| Q4 24 | $10.7M | $-11.0M | ||
| Q3 24 | $112.6M | $267.5M | ||
| Q2 24 | $71.2M | $27.7M |
自由现金流率EXASVSTS
| Q1 26 | — | 4.3% | ||
| Q4 25 | 13.7% | 2.2% | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | 1.2% | ||
| Q1 25 | -0.1% | -1.0% | ||
| Q4 24 | 1.5% | -1.6% | ||
| Q3 24 | 15.9% | 39.1% | ||
| Q2 24 | 10.2% | 4.0% |
资本支出强度EXASVSTS
| Q1 26 | — | 1.4% | ||
| Q4 25 | 3.6% | 2.2% | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | 2.2% | ||
| Q1 25 | 4.4% | 2.0% | ||
| Q4 24 | 5.1% | 2.2% | ||
| Q3 24 | 3.7% | 4.1% | ||
| Q2 24 | 5.1% | 3.0% |
现金转化率EXASVSTS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.54× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 9.66× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
VSTS
| Workplace Supplies | $375.2M | 57% |
| Uniforms | $227.7M | 34% |
| Other | $60.5M | 9% |
